Hopes that anti-tau drugs could join those targeting amyloid as treatments for Alzheimer's disease have been dented by the failure of a phase 2b trial of Johnson & Johnson's posdinemab. The AuTonomy ...

Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to ...

Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the protein that forms toxic tangles in Alzheimer's disease. The findings, ...

Copilot integration in Microsoft 365 apps makes it a snap to generate first drafts, revise text, and get instant summaries for long docs or email threads. Here’s how to use Copilot for writing ...